Breaking News

FDA Approves Marketing for Restylane Silk

June 17, 2014

New technology targets lip area and more.

The US Food and Drug Administration (FDA) has issued marketing clearance for Valeant Pharmaceuticals' Restylane Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.

"We are pleased to have received marketing clearance from the FDA for Restylane Silk so quickly after the approval of Jublia," said J. Michael Pearson, chairman and chief executive officer. "Our R&D team is hitting on all cylinders and demonstrating that Valeant has a successful, output-focused R&D model that concentrates on areas of expertise where we are confident that our investments will pay off."

blog comments powered by Disqus
  • Innovation On Display

    Melissa Meisel, Associate Editor||February 3, 2016
    P&G Beauty Digital Studio showcases new products for 2016

  • Crowning Glory

    Crowning Glory

    Christine Esposito , Associate Editor||February 3, 2016
    Celebrity stylists and experts from leading hair care brands talk about the ingredients and formats driving the styling sector.

  • Electric Slide

    Electric Slide

    Melissa Meisel, Associate Editor||February 3, 2016
    Skin care devices bring anti-aging to the next level